Tilray Medical has launched its first commercial-grown medical cannabis flowers from its Aphria RX GmbH facility in Germany. 

The product will be sold as “Grown in Germany”, explains Tilray’s chief strategy officer and head of international, Denise Faltischek.

“We are excited to launch our Made in Germany premium cannabis products, which marks a significant milestone in our mission to deliver the highest-quality medical cannabis products to patients in Germany,” adding that this helps expand the company’s brand and products in the German market.

Tilray received the first cannabis cultivation licence issued under Germany’s new Cannabis Act in July. This licence allows Aphria RX to cultivate and manufacture cannabis for medical purposes in Germany.

The American cannabis company, which operates in Canada, the United States, Europe, Australia, and Latin America, was the first to receive a cannabis production licence in the country. Canadian cannabis company Aurora and the German company Demecan are also now licensed for production in the country. 

In February 2024, Germany passed the German Medical Cannabis Act, expanding the country’s medical cannabis laws.

Aphria RX has been present in the medical cannabis space in Germany since March 2019, when the company was awarded a licence for the cultivation of medical cannabis in Germany from the German Federal Institute for Drugs and Medical Devices (the “BfArM”). 

Anyone who wishes to cultivate, produce, trade, import, export, dispense, sell, otherwise place on the market, obtain or acquire cannabis for medicinal purposes or cannabis for medical-scientific purposes in Germany requires a permit from the German Federal Institute for Drugs and Medical Devices.

Related Articles

Canadian cannabis companies increasingly exploring export market

June 14, 2023

Aurora Cannabis receives additional German licences

July 25, 2024